Hematology: Antifibrinolytic Medications

Antifibrinolytic Medications

Tranexamic Acid (TXA)

  • Mechanism: Inhibits Plasminogen Conversion to Plasmin
    • Thereby Inhibits Fibrinolysis & Clot Breakdown
    • Higher Affinity (6-10x) for Binding Plasminogen than ε-Aminocaproic Acid
  • Used More Commonly in the U.S. than ε-Aminocaproic Acid
  • Potential Indications:

ε-Aminocaproic Acid (Amicar/EACA)

  • Mechanism: Inhibits Plasminogen Conversion to Plasmin
    • Thereby Inhibits Fibrinolysis & Clot Breakdown
    • Lower Affinity for Binding Plasminogen than TXA
  • Used Less Frequently in the U.S. than TXA
  • Use:
    • Bleeding Due to Hyperfibrinolysis
    • Thrombolytic Overdose
    • Rebleeding After Recent Intracranial Hemorrhage (ICH)
    • Surgical Blood Loss